Alvio is targeted for use in non-regulated respiratory training applications as well as for medical respiratory indications.

In accordance with the Agreement, ADMT has received approximately 23% of QOL's outstanding shares. A

DMT will conclude development of the Alvio technology and submit an application to the FDA for clearance to market in the US.  Once Alvio is finalized, ADMT will be the exclusive manufacturer of Alvio technology and any other forthcoming QOL products.

QOL and ADMT plan to first introduce the non-regulated version of Alvio for sale to the public for breathing training, while preparing submission to FDA for clearance of Alvio for medical applications in the US market and for CE marking for Europe and Canadian CMDCAS.

Over 80 million people in the US and over 1 billion people worldwide suffer with respiratory challenges such as COPD (chronic obstructive pulmonary disease),  CHF (congestive heart failure), and Asthma.

These patients require special breathing monitoring, training, and therapeutic devices in the hospital and at home. Alvio's cloud-connected devices can serve as an enabler to lower costs and improve patient outcomes across the continuum of care in the hospital and at home.

"We are seeing significant interest for Alvio from many major medical institutions, healthcare professionals and international distributors," stated Bez Arkush, founder and president of QOL. "I am so pleased to now be working with ADMT which has the development and regulatory expertise and experience to bring our technology to market."

"We believe our devices are positioned to disrupt the $5+ billion US market and the $6+ billion international respiratory therapy market. Alvio is the world's only fully integrated respiratory therapy platform, mobile connected, respiratory sensor and trainer that can redefine respiratory therapy and training markets," continued Mr. Arkush.

Andre' DiMino, ADMT President concluded "Having an ownership in, and exclusive relationship with QOL brings the meaning of "Strategic Partnership" to a whole new dimension. As recently stated in my letter to shareholders, this is part of our plan to enhance shareholder value and continue to fuel our growth initiatives."

Alvio can provide an end-to-end solution for lung function testing, respiratory training, and data tracking, utilizing an interactive connection among patients, their caregivers, health care providers, and payers.

Alvio employs games and activities to incentivize patients to complete respiratory therapy, overcoming non-compliance issues that plague offerings of conventional respiratory device manufacturers.

 The Alvio platform can solve a major challenge in the healthcare market by offering the next generation of a combination of data and device connectivity – it's Respiratory Therapy 2.0™.